# Clinical Trial Success Rates by Phase: What Healthcare Investors Need to Know > Understanding clinical trial success rates by phase is essential for sizing drug development risk. This explainer breaks down phase-by-phase transition probabilities, explains what drives failures, and shows investors exactly where to verify pipeline claims. ## What Are the Overall Clinical Trial Success Rates by Phase? Across all therapeutic areas, roughly 10 to 15 percent of drug candidates that enter Phase 1 ultimately receive FDA approval. The attrition is steep at every gate, and each phase carries a distinct risk profile that investors must internalize before committing capital to any biotech or pharmaceutical position. Based on aggregated analyses published in peer-reviewed journals and synthesized by groups including the Biotechnology Innovation Organization (BIO), the phase-by-phase probability of success (POS) benchmarks look like this: - **Phase 1 to Phase 2:** approximately 52 to 63 percent of candidates advance - **Phase 2 to Phase 3:** approximately 28 to 40 percent advance (this is the single biggest drop-off) - **Phase 3 to NDA/BLA submission:** approximately 58 to 68 percent advance - **NDA/BLA submission to FDA approval:** approximately 85 to 90 percent receive approval Multiply those probabilities together and you arrive at an end-to-end success rate of roughly 7 to 14 percent, depending on therapeutic area and era of analysis. ## Why Does Phase 2 Have the Highest Failure Rate? Phase 2 is where most value is destroyed and most investor theses collapse. The core reasons are clinical in nature but the warning signs are visible before a trial fails. First, Phase 2 is where proof-of-concept in humans must materialize. Animal models rarely translate perfectly, so early biomarker signals can be misleading. Second, dose selection errors made in Phase 1 often surface as efficacy gaps or unacceptable safety signals when larger, more diverse patient populations are exposed. Third, endpoint selection mistakes, choosing a surrogate endpoint that does not correlate with clinical benefit, doom trials that otherwise show biological activity. Investors should ask these specific questions before a Phase 2 readout: 1. Is the primary endpoint a validated surrogate or a clinical outcome? Check the FDA qualification database at fda.gov/drugs/drug-development-tool-qualification-program. 2. Was the Phase 1 dose chosen using pharmacokinetic/pharmacodynamic modeling, or was it primarily a tolerability exercise? 3. Does the patient population in the trial match the label the company intends to pursue? ## How Do Success Rates Differ by Therapeutic Area? Therapeutic area is one of the strongest predictors of POS, and generic phase benchmarks can mislead investors who do not adjust for disease category. - **Hematology and infectious disease** have historically shown the highest overall success rates, sometimes reaching 25 to 30 percent from Phase 1 to approval, partly because endpoints are well-defined and patient populations are relatively homogeneous. - **Oncology** has one of the lowest overall success rates, typically 5 to 8 percent from Phase 1 to approval, though targeted and cell therapies in specific molecular subtypes have improved that figure meaningfully in recent years. - **Central nervous system (CNS)** disorders carry persistently low POS, often 6 to 9 percent, driven by poor biomarker availability and complex trial design. - **Rare diseases** (orphan drug designation) often show higher approval rates at submission, partly because of smaller, better-defined populations and regulatory flexibility, though Phase 2 still claims many candidates. PubMed (pubmed.ncbi.nlm.nih.gov) is the primary source for peer-reviewed meta-analyses of POS by indication. Searching for terms like "probability of success clinical development" combined with a therapeutic area will surface the most current literature. ## Where Should Investors Verify Pipeline Claims Directly? Company-issued press releases about their pipeline routinely overstate progress. Use primary sources to verify every material claim. - **ClinicalTrials.gov:** Confirms trial registration, actual enrollment numbers, primary endpoints, estimated completion dates, and sponsor amendments. A trial with repeated completion-date extensions or unexplained protocol amendments is a red flag. - **FDA EDGAR submissions via SEC EDGAR (sec.gov/edgar):** 10-K and 10-Q filings contain risk disclosures about trial design that investor presentations omit. - **FDA databases (fda.gov):** The Drugs@FDA database shows approval history; the Clinical Holds database reveals any active safety holds on a program. - **USPTO Patent Database (patents.google.com or USPTO.gov):** Verify patent expiry dates and freedom-to-operate before modeling revenue duration. - **PubMed:** Cross-check whether the mechanism of action has published Phase 2 proof-of-concept in independent academic studies, not just company-sponsored ones. ## What Are the Most Common Investor Mistakes When Reading Trial Data? Several errors recur across the investor base and are consistently costly. **Confusing statistical significance with clinical meaningfulness.** A p-value below 0.05 does not tell you whether the effect size is large enough to change physician prescribing behavior or clear a health technology assessment in a major market. **Ignoring control arm performance.** A drug can appear to work brilliantly in the treatment arm while failing because the control arm performed unusually poorly, a phenomenon called control arm drift. **Assuming a successful Phase 2 guarantees Phase 3 success.** The transition from Phase 2 to Phase 3 is where design quality becomes decisive. Larger, more rigorous Phase 3 trials routinely expose flaws that smaller Phase 2 studies obscured. **Not checking for post-hoc subgroup analysis.** If a company's press release pivots quickly from a primary endpoint miss to a positive subgroup, treat that result as hypothesis-generating only, not confirmatory. ## Quick Checklist Before You Invest in a Clinical-Stage Asset - Confirm trial registration and current status on ClinicalTrials.gov - Identify the primary endpoint type (surrogate vs. clinical outcome) and its FDA qualification status - Benchmark POS against the correct therapeutic area, not the overall 10 to 15 percent average - Review the most recent 10-K risk factors on SEC EDGAR for trial-design disclosures - Search PubMed for independent peer-reviewed evidence supporting the mechanism - Check USPTO for patent cliff timing relative to your investment horizon - Flag any history of clinical holds in the FDA database - Compare company enrollment projections with actual ClinicalTrials.gov enrollment figures ## How MedFuel Intel Automates This Due Diligence Manually cross-referencing ClinicalTrials.gov, SEC EDGAR, FDA databases, USPTO, and PubMed for a single asset can take an analyst eight to twelve hours. MedFuel Intel compresses that into minutes by running AI-powered due-diligence reports that pull directly from primary sources, flag red flags automatically, and benchmark each program against therapeutic-area-specific POS data. Run a free Red Flag Screener on any pipeline asset at https://medfuelintel.com and see exactly where your investment thesis holds up under scrutiny. --- Informational only, not investment advice. --- Source: MedFuel Intel (https://www.medfuelintel.com/geo/article/clinical-trial-success-rates-by-phase). Grounded in primary-source-verified events; verify against SEC, FDA, and ClinicalTrials.gov before any investment decision.